Virtual Library

Start Your Search

Ala Yousif



Author of

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-12 - Right vs Left Lung Cancer – Prognostic Implications (Now Available) (ID 2720)

      08:00 - 18:00  |  Author(s): Ala Yousif

      • Abstract
      • Slides

      Background

      Lung cancer is one of the leading causes of death in the developed world. In Ireland alone there are over 2,500 new cases of lung cancer every year. Several studies set to determine prognostic factors that may play a role in optimising the management of patients with lung cancer. One of the factors currently being studied is the location of lung cancer. The interest in this prognostic factor was partially due to the reported implications of tumour ‘sidedness’ in colon cancer. We conducted a retrospective study to assess if tumour ‘sidedness’ impacts overall survival in a population of Irish patients with non-small cell lung cancer.

      Method

      In this study we selected patients with a diagnosis of non-small cell lung cancer (stage I – stage IV) who received systemic therapy at Sligo University Hospital between 2011-2018. The cut-off date for inclusion was the 1st of March 2019. The primary end point was overall survival. The study was reviewed by the ethics board of Sligo University Hospital who approved data collection and waived consent for this study.

      Result

      A total of 76 patients were identified. Of them 41% (n=31) were females and 59% (n=45) were males. 70% (n=53) had a right-sided lung cancer and 30% (n=23) had a left-sided lung cancer. There were 3 patients with stage I disease, 13 patients with stage II disease, 26 patients with stage III disease and 34 patients with stage IV disease. Median overall survival for all stages was 19.0 ± 5.0 months (95% CI 9.2-28.8) for right lung cancers and 15.0 ± 7.4 months (95% CI 0.6-29.4) for left lung cancers. For stage III lung cancers median overall survival was 34.0 ± 6.7 months (95% CI 20.8-47.2) for right lung cancers and 13.0 ± 4.0 months (95% CI 5.2-20.8) for left lung cancers. For stage IV lung cancers the median overall survival was 12.0 ± 1.5 months (95% CI 9.0-15.0) for right lung cancers and 13.0 ± 13.4 months (95% CI 0.0-39.2) for left lung cancers.

      Conclusion

      We did not observe a significant difference in outcome between right-sided and left-sided lung cancers when assessing patients of all stages combined or for the stage IV sub-group. However, in stage III lung cancer, patients with right lung tumours seem to have a better outcome than patients with left lung tumours. Our data are limited by the fact that this is a single institute study with only a modest number of patients, 76 in total. A larger study will be required to assess if the trend observed holds true, the factors behind it and how it may contribute to optimising the management of lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.